The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer

Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viab...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncogenesis
Päätekijät: Xu, Meng-Dan, Liu, Lu, Wu, Meng-Yao, Jiang, Min, Shou, Liu-Mei, Wang, Wen-Jie, Wu, Jing, Zhang, Yan, Gong, Fei-Ran, Chen, Kai, Tao, Min, Zhi, Qiaoming, Li, Wei
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255842/
https://ncbi.nlm.nih.gov/pubmed/30478299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0102-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia